Pemphigus Vulgaris – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Pemphigus Vulgaris – Pipeline Review, H2 2017’, provides an overview of the Pemphigus Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris

The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects

The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

arGEN-X BV

Biogen Inc

HanAll Biopharma Co Ltd

Immunomedics Inc

Novartis AG

Principia Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pemphigus Vulgaris - Overview 6

Pemphigus Vulgaris - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Pemphigus Vulgaris - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Pemphigus Vulgaris - Companies Involved in Therapeutics Development 20

arGEN-X BV 20

Biogen Inc 20

HanAll Biopharma Co Ltd 21

Immunomedics Inc 21

Novartis AG 21

Principia Biopharma Inc 22

Pemphigus Vulgaris - Drug Profiles 23

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DPC-006 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

efgartigimod alfa - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HL-161 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PRN-1008 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

rituximab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

SYNT-001 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

VAY-736 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

veltuzumab - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Pemphigus Vulgaris - Dormant Projects 46

Pemphigus Vulgaris - Discontinued Products 47

Pemphigus Vulgaris - Product Development Milestones 48

Featured News & Press Releases 48

Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-113 48

Sep 26, 2017: argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris 48

Sep 18, 2017: Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting 49

Jul 11, 2017: Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris 49

Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris 50

Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 51

Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pemphigus Vulgaris – Pipeline by arGEN-X BV, H2 2017 20

Pemphigus Vulgaris – Pipeline by Biogen Inc, H2 2017 20

Pemphigus Vulgaris – Pipeline by HanAll Biopharma Co Ltd, H2 2017 21

Pemphigus Vulgaris – Pipeline by Immunomedics Inc, H2 2017 21

Pemphigus Vulgaris – Pipeline by Novartis AG, H2 2017 22

Pemphigus Vulgaris – Pipeline by Principia Biopharma Inc, H2 2017 22

Pemphigus Vulgaris – Dormant Projects, H2 2017 46

Pemphigus Vulgaris – Discontinued Products, H2 2017 47

List of Figures

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports